For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-
mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known …

Defects in alternative splicing are frequently found in human tumors and result either from
mutations in splicing‐regulatory elements of specific cancer genes or from changes in the …

Resistance to chemotherapy and molecularly targeted therapies is a major problem facing
current cancer research. The mechanisms of resistance to'classical'cytotoxic …

The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2
family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic …

The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …

Purpose To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a
selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer …

ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …

Chemoresistant metastatic relapse of minimal residual disease plays a significant role for
poor prognosis of cancer. Growing evidence supports a critical role of cancer stem cell …